Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

McMaster University

$17,500.00

Fast I(n)Dentification of PATHogens in Neonates (FINDPATH-N): A prospective pilot study of next generation sequencing for pathogen identification in neonates with suspected sepsis

EF 2018-19

Résumé
Sepsis is a life-threatening condition caused by the body’s reaction to a serious infection. Sepsis is common in neonates (babies under one month of age) and is a major cause of death and disability. The current gold-standard test for sepsis in neonates is a blood culture, which incubates the blood followed by microscopy to identify which bacteria have grown. However, blood culture does not detect bacteria in many cases where doctors think that neonates actually do have sepsis. There is a need for an accurate and fast test for sepsis. Next generation sequencing (NGS) is a technique used to quickly sequence DNA. NGS can detect very small amounts of bacterial or viral DNA in a blood sample and can also provide information on which antibiotics might work through sequencing resistance genes. The bacteria do not have to be alive still, unlike blood culture. To investigate the feasibility of using NGS in neonates, we will perform a study at McMaster Children’s Hospital Neonatal Intensive Care Unit. Neonates with suspected sepsis will have both a blood culture and a 0.7 mL blood sample for NGS drawn. Neonates who are already on IV antibiotics, already recently enrolled in the study or are palliative will be excluded. Medical chart review of participating neonates will record culture results, physical symptoms, lab results and antibiotic treatment. Our primary outcome is the ability to enroll neonates and successfully collect and process their blood using NGS. Additionally, the ability of NGS to detect bacteria will be compared to the gold-standard blood culture taken at the same time. This study would be an important step to investigate the potential of NGS to improve the diagnosis and treatment of sepsis in neonates.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
406395
Name
Klowak Jennifer A
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Fast I(n)Dentification of PATHogens in Neonates (FINDPATH-N): A prospective pilot study of next generation sequencing for pathogen identification in neonates with suspected sepsis
Programtype2
Studentship Programs
Orgnameinp2
McMaster University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Antibiotic Resistance; Bacteria; Blood Culture; Diagnostic Testing; Dna; Neonates; Next Generation Sequencing; Pathogen; Pediatrics; Sepsis
Abstract
Sepsis is a life-threatening condition caused by the body’s reaction to a serious infection. Sepsis is common in neonates (babies under one month of age) and is a major cause of death and disability. The current gold-standard test for sepsis in neonates is a blood culture, which incubates the blood followed by microscopy to identify which bacteria have grown. However, blood culture does not detect bacteria in many cases where doctors think that neonates actually do have sepsis. There is a need for an accurate and fast test for sepsis. Next generation sequencing (NGS) is a technique used to quickly sequence DNA. NGS can detect very small amounts of bacterial or viral DNA in a blood sample and can also provide information on which antibiotics might work through sequencing resistance genes. The bacteria do not have to be alive still, unlike blood culture. To investigate the feasibility of using NGS in neonates, we will perform a study at McMaster Children’s Hospital Neonatal Intensive Care Unit. Neonates with suspected sepsis will have both a blood culture and a 0.7 mL blood sample for NGS drawn. Neonates who are already on IV antibiotics, already recently enrolled in the study or are palliative will be excluded. Medical chart review of participating neonates will record culture results, physical symptoms, lab results and antibiotic treatment. Our primary outcome is the ability to enroll neonates and successfully collect and process their blood using NGS. Additionally, the ability of NGS to detect bacteria will be compared to the gold-standard blood culture taken at the same time. This study would be an important step to investigate the potential of NGS to improve the diagnosis and treatment of sepsis in neonates.
Competitiondate
201812
Approvedterm2
1 yr 0 mth
Pinamesdelim
Klowak, Jennifer A
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~